Azilva Tablets special drug use surveillance Hypertension complicated by diabetes

TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点目标入组 300 人开始时间: 2014年3月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients with hypertension who meet all the following criteria will be enrolled:
•[1] Patients who has complications of diabetes mellitus
•[2] Patients who is on monotherapy with ARBs (other than azilsartan) as antihypertensive treatment
•(Patients who have continued monotherapy with the same ARB product for at least 8 weeks at the time of Step-1* of subject enrollment and will continue such treatment until the first administration of Azilva Tablets)
•[3] Patients who has a systolic blood pressure of >= 130 mmHg and/or diastolic blood pressure of 80 >= mmHg at the examination performed at the medical institution
•[4] Patients who is an outpatient
•[5] Patient who keeps a regular lifestyle and whose usual waking time is between 4 a.m. and 9:30 a.m.
•*For this surveillance, subject enrollment will be performed in two divided steps: Step-1 (at the first hospital visit before prescription of Azilva Tablets) and Step-2 (at the time of prescription of Azilva Tablets).

发起方

TAKEDA PHARMACEUTICAL COMPANY LTD.